A new approach for the prophylactic improvement of surgical scarring: avotermin (TGF beta 3).
Patients and physicians are concerned about scarring resulting from surgery, and patients, in particular, value even small improvements in scarring. Translational research into the processes involved in scarring at the molecular, cellular, and tissue levels has facilitated the discovery and development of new biological approaches for improving scarring. This article highlights research concerning avotermin (human recombinant TGF beta 3), the first in a new class of prophylactic medicines that may promote the regeneration of normal skin and improve scar appearance.
Young
V Leroy
VL
BodyAesthetic Plastic Surgery and Skincare Center, 969 North Mason Road, Suite 170, St. Louis, MO 63141, USA. leroyyoungmd@bodyaesthetic.com
Bush
James
J
O'Kane
Sharon
S
D002921:Cicatrix / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D011183:Postoperative Complications; D011994:Recombinant Proteins / Q000627:therapeutic use*; D019651:Plastic Surgery Procedures / Q000379:methods*; D053782:Transforming Growth Factor beta3 / Q000627:therapeutic use*
D011994:Recombinant Proteins; D053782:Transforming Growth Factor beta3